BiotechTube

BCT197 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pulmonary Disease, Chronic Obstructive

Conditions

Pulmonary Disease, Chronic Obstructive

Trial Timeline

Aug 1, 2016 → Nov 28, 2017

NCT ID
NCT02700919

About BCT197 + Placebo

BCT197 + Placebo is a phase 2 stage product being developed by Mereo BioPharma for Pulmonary Disease, Chronic Obstructive. The current trial status is completed. This product is registered under clinical trial identifier NCT02700919. Target conditions include Pulmonary Disease, Chronic Obstructive.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02700919Phase 2Completed

Competing Products

20 competing products in Pulmonary Disease, Chronic Obstructive

See all competitors
ProductCompanyStageHype Score
AP01Avalyn PharmaceuticalsPhase 2
44
macitentan 10 mgBML, Inc.Phase 3
76
tadalafil + tadalafilEli LillyPhase 3
77
CS1 AdministrationCereno ScientificPhase 2
47
CS1Cereno ScientificPre-clinical
18
TX000045- Dose A + TX000045- Dose B + PlaceboTectonic TherapeuticPhase 2
44
Dose A KER-012 + Dose B KER-012 + Dose C KER-012 + Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeksKeros TherapeuticsPhase 2
44
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + PlaceboRein TherapeuticsPhase 1
25
LTI-03 + PlaceboRein TherapeuticsPhase 1
25
LTI-03 + PlaceboRein TherapeuticsPhase 2
44
Satralizumab (Genetical Recombination)Chugai PharmaceuticalPhase 2
52
DS-1040b + Placebo + EnoxaparinDaiichi SankyoPhase 1/2
41
DS-9231 + PlaceboDaiichi SankyoPhase 2
52
RegadenosonAstellas PharmaPre-clinical
23
Reldesemtiv + PlaceboAstellas PharmaPhase 2
52
MonteplaseEisaiApproved
85
lysozyme 90 mg + PlaceboEisaiApproved
85
Prednisolone + VoriconazoleCiplaPhase 2/3
65
Drotrecogin Alfa (Activated) + Enoxaparin + Placebo + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated)Eli LillyPhase 2
52
tadalafil and ambrisentan upfront combination therapyEli LillyApproved
85

Other Products from Mereo BioPharma

Alvelestat (MPH966)Phase 2
44
Pemetrexed + Carboplatin + demcizumabPhase 2
44
Nivolumab + EtigilimabPhase 2
44
BGS649 + PlaceboPhase 2
44
Placebo Oral Tablet + Alvelestat oral tablet - dose 1 + Alvelestat oral tablet - dose 2Phase 2
44